---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-005633"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:39:39.190931+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences closes $4.5M public stock & warrant offering, over-allotment fully exercised

## Summary
- Offering of 4,312,500 shares + warrants for 2,156,250 shares at $2.41 per set (2 shares + 1 warrant).
- Net proceeds of $4.5 million; warrants exercisable at $1.40 per share for 5 years.
- Proceeds to fund working capital, product development, regulatory submissions, and commercialization.
- Newbridge Securities acted as sole underwriter; warrants will not be listed on any exchange.

## SEC filing metadata
- accession: 0001654954-23-005633
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/0001654954-23-005633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-005633
- JSON: https://secwatch.observer/filing/0001654954-23-005633.json
- Plain text: https://secwatch.observer/filing/0001654954-23-005633.txt

## Key facts
- Material Agreements
  ENDRA Life Sciences Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at approximately $4.5 million (effective 2023-04-27).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Newbridge Securities Corporation
  - Value: approximately $4.5 million
  - Effective: 2023-04-27
  source text: On April 27, 2023, ENDRA Life Sciences Inc. (the “Company,” “we,” “us” and “our”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 3,750,000 shares of our common stock and warrants to purchase up to 1,875,000 shares of our common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/0001654954-23-005633-index.htm
- Material Agreements
  ENDRA Life Sciences Inc. entered into Warrant Agreement with VStock Transfer, LLC (effective 2023-05-02).
  - Action: entry
  - Counterparty: VStock Transfer, LLC
  - Effective: 2023-05-02
  source text: On May 2, 2023, the Company entered into a Warrant Agent Agreement setting forth the terms and conditions of the warrants (the “Warrant Agreement”) with its transfer agent, VStock Transfer, LLC, which will act as warrant agent for the warrants.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/0001654954-23-005633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.